Green Cross Labcell, a Green Cross affiliate that develops drugs for incurable diseases, posted 34.5 billion won (US $29.8 million) in sales and operating profit of 2.3 billion won last year. The initial public offering is priced at 18,500 won.
ST Pharm, launched in 2008, recorded 138 billion won in sales and 25.2 billion won in operating profit last year. The IPO is priced at 29,000 won.
By Ahn Sung-mi (firstname.lastname@example.org)